Octave Bioscience
Ferhan Qureshi has a long and varied work experience, beginning in 1997 as a Summer Intern at ALZA Corporation. In 1998, they took on the role of Supervisor: Peptide Antibody Analysis at Santa Cruz Biotechnology. Ferhan then moved to Genentech in 2000, where they worked as a Supervisor. In 2007, they became Group Leader at Aviir, Inc. and in 2009, they were appointed Director - Assay Development and Manufacturing at Crescendo Bioscience. Most recently, in 2018, they took on the role of Vice President - Biomarker Product Development at Octave Bioscience.
Ferhan Qureshi has a Bachelor's degree in Cell/Cellular and Molecular Biology from the University of California, Santa Cruz. Ferhan also holds a LEAN Knowledge Certificate from the Society of Manufacturing Engineers (SME) | Chapter 4.
This person is not in any offices
Octave Bioscience
Octave Bioscience’s Comprehensive Care Platform provides a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. It provides multiple layers of insight to provide a 360 degree view with a longitudinal perspective of disease progression. The first layer measures the patient’s underlying biology with blood based biomarkers that quantitatively and objectively assess inflammation and immune modulation. The second layer includes advanced measurement using improved MRI readings and interpretation to reveal more insights at the CNS layer, including the brain and spine. The final layer features real time tracking of symptoms via monitoring with mobile tools, sensors and wearables to identify changes in disease and alert care teams. All of this data is integrated into protocols, supported by decision support tools and feeds into a dashboard for ease of use. The Octave Platform allows individual and population views to facilitate better stratification and contextual interventions.